TEL
AVIV, Israel, Oct. 26,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced the company will present at major U.S. scientific
conferences in November, including an oral presentation on primary
sclerosing cholangitis and a poster at the AASLD The
Liver Meeting® 2023, as well as a poster presentation on
the role of Chemomab's CCL24 target in manifestations of systemic
sclerosis at the American College of Rheumatology Convergence 2023.
Further details of the presentations will be released in
November.
AASLD The Liver Meeting® 2023, Boston, MA, Nov. 10-14,
2023
|
Date:
|
Nov. 13,
2023
|
|
Time:
|
4:30pm ET
|
|
Format:
|
Oral
presentation: Serum proteomics reveals unique association
of CCL24 with disease-related pathways and signatures in primary
sclerosing cholangitis
|
|
Presenter:
|
Ilan Vaknin, PhD, Vice
President of R&D, Chemomab Therapeutics, Ltd.
|
|
Authors:
|
Tom Snir, Raanan
Greenman, Revital Aricha, John Lawler, Francesca Saffioti, Douglas
Thorburn, Massimo Pinzani, Adi Mor, Ilan Vaknin
|
|
Session:
|
Room 312 - Breaking the
Chains of Cholestatic Liver Injury: Advancements and Promising
Treatment Strategies
|
|
Information:
|
The Liver Meeting |
AASLD
|
AASLD The Liver Meeting® 2023, Boston, MA, Nov. 10-14,
2023
|
Date:
|
Nov. 11,
2023
|
|
Time:
|
1:00-2:00 pm
ET
|
|
Format:
|
Poster
presentation: CM-101, a CCL24 neutralizing antibody, showed
improvements in inflammatory, fibrotic, and metabolic pathways in
patients with NASH: Proteomics analysis of a Phase 2a
study
|
|
Presenter:
|
Matt Frankel, MD,
Chief Medical Officer & Vice President of Drug
Development, Chemomab Therapeutics
|
|
Authors:
|
Revital Aricha, Tom
Snir, Ilan Vaknin, John Lawler, Adi Mor, Matt Frankel
|
|
Session:
|
Poster session
Hall C – 2nd level
|
|
Information:
|
The Liver Meeting |
AASLD
|
American College of Rheumatology Convergence 2023 –
San Diego, CA, Nov.10-15,
2023
|
Date:
|
Nov. 14,
2023
|
|
Time:
|
9:00-11:00 am
PT
|
|
Format:
|
Poster
presentation: The Involvement of CCR3-CCL24 Axis in
Endothelial to Mesenchymal Transition Process and Pulmonary
Arterial Hypertension in Systemic Sclerosis Patients
|
|
Presenter:
|
Ilan Vaknin, PhD,
Vice President of R&D, Chemomab Therapeutics
|
|
Authors:
|
Itzchak Amoyal,
Tzipi Hornik-Lurie, Tali Zitman-Gal, Hilit Levy, Ilan Vaknin Liat
Drucker, Ishai Heusler, Yair Levy, Shelly Tartakover
Matalo
|
|
Session:
|
Poster Session C,
Systemic Sclerosis & Related Disorders – Clinical Poster III:
Translational Science
|
|
Information:
|
rheumatology.org/annual-meeting
|
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to neutralize CCL24 activity. In preclinical and clinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported encouraging results from three clinical trials of
CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver
fibrosis trial in NASH patients and an investigator-initiated study
in patients with severe lung injury. The CM-101 program for the
treatment of systemic sclerosis is Phase 2-ready and a Phase 2
trial in primary sclerosing cholangitis patients is ongoing, with
topline data expected in the second half of 2024. For more
information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-upcoming-scientific-conferences-301968462.html
SOURCE Chemomab Therapeutics, Ltd.